TY - JOUR
T1 - Imaging systemic inflammatory networks in ischemic heart disease
AU - Nahrendorf, Matthias
AU - Frantz, Stefan
AU - Swirski, Filip K.
AU - Mulder, Willem J.M.
AU - Randolph, Gwendalyn
AU - Ertl, Georg
AU - Ntziachristos, Vasilis
AU - Piek, Jan J.
AU - Stroes, Erik S.
AU - Schwaiger, Markus
AU - Mann, Douglas L.
AU - Fayad, Zahi A.
N1 - Publisher Copyright:
© 2015 American College of Cardiology Foundation.
PY - 2015/4/21
Y1 - 2015/4/21
N2 - While acute myocardial infarction mortality declines, patients continue to face reinfarction and/or heart failure. The immune system, which intimately interacts with healthy and diseased tissues through resident and recruited leukocytes, is a central interface for a global host response to ischemia. Pathways that enhance the systemic leukocyte supply may be potential therapeutic targets. Pre-clinically, imaging helps to identify immunity's decision nodes, which may serve as such targets. In translating the rapidly-expanding pre-clinical data on immune activity, the difficulty of obtaining multiple clinical tissue samples from involved organs is an obstacle that whole-body imaging can help overcome. In patients, molecular and cellular imaging can be integrated with blood-based diagnostics to assess the translatability of discoveries, including the activation of hematopoietic tissues after myocardial infarction, and serve as an endpoint in clinical trials. In this review, we discuss these concepts while focusing on imaging immune activity in organs involved in ischemic heart disease.
AB - While acute myocardial infarction mortality declines, patients continue to face reinfarction and/or heart failure. The immune system, which intimately interacts with healthy and diseased tissues through resident and recruited leukocytes, is a central interface for a global host response to ischemia. Pathways that enhance the systemic leukocyte supply may be potential therapeutic targets. Pre-clinically, imaging helps to identify immunity's decision nodes, which may serve as such targets. In translating the rapidly-expanding pre-clinical data on immune activity, the difficulty of obtaining multiple clinical tissue samples from involved organs is an obstacle that whole-body imaging can help overcome. In patients, molecular and cellular imaging can be integrated with blood-based diagnostics to assess the translatability of discoveries, including the activation of hematopoietic tissues after myocardial infarction, and serve as an endpoint in clinical trials. In this review, we discuss these concepts while focusing on imaging immune activity in organs involved in ischemic heart disease.
KW - atherosclerosis
KW - heart failure
KW - hematopoiesis
KW - leukocytes
KW - myocardial infarction
KW - spleen
UR - http://www.scopus.com/inward/record.url?scp=84928027689&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2015.02.034
DO - 10.1016/j.jacc.2015.02.034
M3 - Review article
C2 - 25881940
AN - SCOPUS:84928027689
SN - 0735-1097
VL - 65
SP - 1583
EP - 1591
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 15
ER -